Alvotech (ALVO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 67 | 37 | 83 | 91 | 490 | 586 | 492 | 594 |
| Operating profit | $m | 78 | 47 | ||||||
| Net profit | $m | -170 | -102 | -514 | -552 | -232 | 28 | -180 | -6 |
| EPS reported | $ | 0.10 | -0.63 | ||||||
| Operating cashflow per share | $ | -0.18 | -0.56 | ||||||
| Capex per share | $ | 0.23 | 0.28 | ||||||
| FCF per share | $ | -0.41 | -0.84 | ||||||
| Free cash flow | $m | -115 | -300 | ||||||
| Net debt | $m | 1,127 | 1,309 | ||||||
| Book value equity | $m | -284 | -191 | ||||||
| Book value per share | $ | -1.02 | -0.54 | ||||||
| Number of shares | m | 279.19 | 356.82 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 51.30 | - | ||||||
| P/B LTM | x | -5.03 | -7.48 | ||||||
| P/S LTM | x | 2.44 | 2.91 | ||||||
| P/FCF LTM | x | -12.49 | -4.77 | ||||||
| EV/EBITDA LTM | x | 8.38 | -1,901.07 | ||||||
| EV/Sales LTM | x | 4.62 | 6.32 | ||||||
| Earnings Yield LTM | % | +1.95% | -9.46% | ||||||
| FCF Yield | % | -8.01% | -20.96% | ||||||
| Quality | |||||||||
| ROE | % | -9.81% | +76.83% | ||||||
| ROIC | % | +1.30% | +3.61% | ||||||
| Operating margin | % | +13.34% | +9.62% | ||||||
| Gross margin | % | +59.82% | +60.45% | ||||||
| FCF/Sales | % | -19.56% | -61.03% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +19.74% | +0.46% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +12.30% | -32.05% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.08 | -0.21 | ||||||
| Net Debt/EBITDA | x | 3.95 | -918.62 | ||||||
| EBIT/Net interest | x | 0.52 | 0.30 | ||||||
| Net debt/market cap | % | +90.70% | +73.24% | ||||||
| Net debt/Equity | x | -3.96 | -6.84 | ||||||
| Gross debt/equity | x | -5.09 | -7.58 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free